Experts discuss how synthetic growth factors work and share application examples and data using these synthetic peptides for cell therapy and regenerative medicine.

The production of conventional growth factors and cytokines for regenerative medicine, cell therapy products, and cultivated meat is faced with challenges such as lot-to-lot quality variation, contamination, low stability, and high manufacturing costs. PeptiGrowth Inc. has developed synthetic peptides that offer a solution to these challenges while still retaining the same capabilities of receptor activation, cell proliferation, and differentiation as conventional growth factors.

In this webinar, Dr. Kosuke Minamihata and Dr. Jes Kuruvilla share application examples of synthetic peptide growth factors in cell culture models and the key benefits of using their products.

Key Topics Include:

  • How synthetic peptide growth factors work
  • Functional properties and application data of synthetic peptide growth factors
  • Benefits of using synthetic peptide growth factors in cell culture



Technical Support Manager for Marketing
PeptiGrowth, Inc.

Kosuke Minamihata earned his PhD in protein engineering from Kyushu University in Japan, with a focus on site-specific modification of proteins using enzymatic reactions. He joined the University of Tokyo and worked as a Postdoctoral Fellow and Assistant professor for 3.5 years. Then, he joined Kyushu University in 2016 as a Research Associate and helped set up KAICO Ltd., which provides growth factors and contracted protein synthesis service using silkworm-baculovirus expression systems. He was a part of the sales and development team at KAICO Ltd, for 2 years. He returned to Kyushu University as a full-time Assistant Professor in 2020 before joining his current position at PeptiGrowth-Mitsubishi in October 2022, where he is the Technical Support Manager for marketing.

Sales and Development Manager
MIFI Bioceuticals

Jes Kuruvilla received his PhD in Cell and Molecular Biology with a background in developing humanized animal models for studying viral infections. During his post-doctoral fellowships he gathered expertise in studying stem cells of the gastrointestinal (GI) tract and its regeneration in response to radiation damage. He transitioned into the industry supporting stem cell scientists to develop various iPSC and hES lines as well as adult stem cells into organoids over the recent years. In MIFI Bioceuticals, he is in charge of business development for PeptiGrowth’s unique synthetic peptide growth factors in North America. MIFI Bioceuticals is a division of Mitsubishi International Food Ingredients, based in NJ, the USA.

Production Partner

PeptiGrowth, Inc.

Currently, numerous growth factors are known, but in order to realize a completely Xeno-free culture medium, multiple growth factors must be replaced by chemically synthesized products. PeptiGrowth utilizes PeptiDream’s proprietary technology (PDPS) to become world-first to comprehensively develop numerous Growth Factor Alternative Peptides. We will contribute to the expansion of regenerative medicine and cell therapy by providing chemically synthesized Growth Factor Alternative Peptides with uniform quality.

Additional Content From

Related Content

Cut and Paste of Myosin Binding Protein-C in Striated Muscles

Cut and Paste of Myosin Binding Protein-C in Striated Muscles

Dr. Samantha Harris discusses the development of three new mouse models in her lab, engineered to target and replace specific myosin binding protein-C paralogs in muscle fibers and impact of their mutations on skeletal and cardiac muscle diseases.